Clinical implications of the polymorphic interaction of murine IgG2b and IgG1 with human Fc receptors
- 1 December 1993
- journal article
- review article
- Published by Elsevier in Transplant Immunology
- Vol. 1 (4) , 250-252
- https://doi.org/10.1016/0966-3274(93)90032-4
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Proteolysis Increases the Fc‐Mediated Binding of Murine IgG2b to Human EBV‐Transformed B Cells, but Decreases the Expression of FcγRII and FcγRIIScandinavian Journal of Immunology, 1993
- ABSENCE OF CLINICAL SYMPTOMS FOLLOWING THE FIRST INJECTION OF ANTI-T CELL RECEPTOR MONOCLONAL ANTIBODY (BMA 031) DESPITE ISOLATED TNF RELEASETransplantation, 1993
- The Human Fc Receptor for Mouse IgG2b on Monocytes and EBV‐B Cells is Functionally Inhibited by Anti‐HLA Class II AntibodiesScandinavian Journal of Immunology, 1993
- TREATMENT OF ACUTE GRAFT-VERSUS-HOST DISEASE WITH A NONMITOGENIC ANTI-CD3 MONOCLONAL ANTIBODYTransplantation, 1992
- Monoclonal antibodies in renal transplantation: a reviewTransplant International, 1992
- Immunosuppression by T Cell Antibodies in Renal TransplantationNephron, 1992
- Human Fcγ receptor II: a standby receptor activated by proteolysis?Immunology Today, 1990
- T cell activation by monoclonal antibodies directed to different epitopes on the human T cell receptor/CD3 complex: Evidence for two different modes of activationEuropean Journal of Immunology, 1989
- First clinical experience with a new TCR/CD3-monoclonal antibody (BMA 031) in kidney transplant patientsTransplant International, 1988
- Human Macrophages Armed with Murine Immunoglobulin G2a Antibodies to Tumors Destroy Human Cancer CellsScience, 1983